C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes. In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York.

Cyclica operates in the exciting intersection of Technology and Life Sciences/Healthcare. Cyclica enhances drug discovery by harnessing big data and predictive analytics through it's patented cloud based platform, Ligand Express™ (www.ligandexpress.com). Traditional design of small molecule therapies has focused on specific, disease-associated protein targets which has led to the development of many breakthrough medicines. However, once a drug enters the body it interacts with dozens, if not hundreds, of proteins before it is excreted. These off-target interactions can represent threats to the safety of a drug, or potential repurposing opportunities. Cyclica harnesses biophysics, biological data, and artificial intelligence (AI) to help pharmaceutical companies navigate the drug discovery pipeline by assessing the safety and efficacy of drugs. Whether pre-clinical, clinical, or FDA approved, Cyclica's patented, drug-centric, structure-based and AI-augmented platform, Ligand Express™ , offers novel insight and analysis into a drugs’ poylpharmacology (i.e. all the proteins a drug interacts with). By focusing on a small molecule structure and its polypharmacological profile, we distinguish ourselves with virtual screening technologies that are specific for a protein structure. We further augment our structural information with AI to drive our biophysical simulations. Learn more through a short video: https://www.youtube.com/watch?v=pYtLKSZB-r0 or by visiting our website at https://cyclicarx.com/ligandexpress/. Our publications, validation notes, and case studies can be found here: https://cyclicarx.com/documentation/

Cyclica operates in the exciting intersection of Technology and Life Sciences/Healthcare. Cyclica enhances drug discovery by harnessing big data and predictive analytics through it's patented cloud based platform, Ligand Express™ (www.ligandexpress.com). Traditional design of small molecule therapies has focused on specific, disease-associated protein targets which has led to the development of many breakthrough medicines. However, once a drug enters the body it interacts with dozens, if not hundreds, of proteins before it is excreted. These off-target interactions can represent threats to the safety of a drug, or potential repurposing opportunities. Cyclica harnesses biophysics, biological data, and artificial intelligence (AI) to help pharmaceutical companies navigate the drug discovery pipeline by assessing the safety and efficacy of drugs. Whether pre-clinical, clinical, or FDA approved, Cyclica's patented, drug-centric, structure-based and AI-augmented platform, Ligand Express™ , offers novel insight and analysis into a drugs’ poylpharmacology (i.e. all the proteins a drug interacts with). By focusing on a small molecule structure and its polypharmacological profile, we distinguish ourselves with virtual screening technologies that are specific for a protein structure. We further augment our structural information with AI to drive our biophysical simulations. Learn more through a short video: https://www.youtube.com/watch?v=pYtLKSZB-r0 or by visiting our website at https://cyclicarx.com/ligandexpress/. Our publications, validation notes, and case studies can be found here: https://cyclicarx.com/documentation/